Securing investment and building long-term shareholder value depends on a clear and compelling investment proposition.

Our team combines deep life sciences expertise with direct experience in venture capital, investor relations and corporate strategy. We understand what investors, analysts and potential partners look for when evaluating opportunities and how companies can position themselves effectively at different stages of growth.

We work with leadership teams to develop a differentiated equity story, articulate value-driving milestones and create communications programmes that support financing, partnering and corporate development objectives. Whether preparing for a financing round, strategic transaction or public market engagement, we help ensure your story resonates with the audiences that matter most.

Services

  • Strategic financial communications counsel
  • Equity story development
  • Investor messaging & positioning
  • Investor presentations & materials
  • Business plans
  • Investor relations
  • Investor websites
  • Analyst relations
  • Financial media relations
  • Results announcements
  • Annual & interim reports
  • Investment conferences & roadshows
  • Financing & transaction communications
  • Support with mergers and acquisitions

Case Studies

Amphista Therapeutics

Announcing the company’s Series A financing, leading to raised awareness with potential partners, investors and employees.

Amphista Therapeutics: Series B Financing

Announcing the company's Series B financing, which will be used to accelerate the growing pipeline of potent and selective bifunctional molecules and to extend its proprietary TPD platform.

Epitopea USD $31 Million Pre-Series A Financing

Supporting Epitopea’s $31M Pre-Series A financing with high-impact media coverage, raising visibility for CryptoMap™ and strengthening investor and partner engagement.

ExeVir Bio EIB funding case study

Announcing the company's 25 million Euro financing from EIB to advance ExeVir’s COVID19 therapeutic

Medicxi

To launch Index’s new spin-out life sciences fund and publicise its first closing.

MitoRx Case Study: Promoting a published paper

Promoting R&D findings on small molecule mitochondrial modulators

Pneumagen

Raising visibility of its technology platform for the treatment for COVID-19 and supporting a new website and fundraising announcement.

Raising the profile of Scarlet Therapeutics

Supporting Scarlet Therapeutics in communicating a major platform validation milestone and £3.2 million seed financing, raising visibility with investors, partners and industry stakeholders.

TILT Biotherapeutics €22 Million Financing

Supporting TILT Biotherapeutics and their final close of €22 Million financing

Vaccitech

Support with corporate and investor materials and media relations supporting the partnership of its ChAdOx platform with AstraZeneca for a COVID-19 vaccine.

Vaccitech IPO

Coordinated a communications plan with key stakeholders to maximise visibility of Vaccitech's Series B financing and NASDAQ IPO listing 

Amphista Therapeutics

Announcing the company’s Series A financing, leading to raised awareness with potential partners, investors and employees.

Amphista Therapeutics: Series B Financing

Announcing the company's Series B financing, which will be used to accelerate the growing pipeline of potent and selective bifunctional molecules and to extend its proprietary TPD platform.

Epitopea USD $31 Million Pre-Series A Financing

Supporting Epitopea’s $31M Pre-Series A financing with high-impact media coverage, raising visibility for CryptoMap™ and strengthening investor and partner engagement.

ExeVir Bio EIB funding case study

Announcing the company's 25 million Euro financing from EIB to advance ExeVir’s COVID19 therapeutic

Medicxi

To launch Index’s new spin-out life sciences fund and publicise its first closing.

MitoRx Case Study: Promoting a published paper

Promoting R&D findings on small molecule mitochondrial modulators

Pneumagen

Raising visibility of its technology platform for the treatment for COVID-19 and supporting a new website and fundraising announcement.

Raising the profile of Scarlet Therapeutics

Supporting Scarlet Therapeutics in communicating a major platform validation milestone and £3.2 million seed financing, raising visibility with investors, partners and industry stakeholders.

TILT Biotherapeutics €22 Million Financing

Supporting TILT Biotherapeutics and their final close of €22 Million financing

Vaccitech

Support with corporate and investor materials and media relations supporting the partnership of its ChAdOx platform with AstraZeneca for a COVID-19 vaccine.

Vaccitech IPO

Coordinated a communications plan with key stakeholders to maximise visibility of Vaccitech's Series B financing and NASDAQ IPO listing